Needham & Company initiates coverage of Chelsea Therapeutics (Nasdaq: CHTP) with a Buy rating and $7 price target.

Needham analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE